Mobile HIV screening in Cape Town, South Africa: Clinical impact, cost and cost-effectiveness

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Bassett, Ingrid V ^a,b   Govindasamy, Darshini ^c   Erlwanger, Alison S ^a   Hyle, Emily P ^a   Kranzer, Katharina ^d   Van Schaik, Nienke ^c   Noubary, Farzad ^e,f   Paltiel, A David ^g   Wood, Robin ^c,h   Walensky, Rochelle P ^a,b,i   Losina, Elena ^a,b,i,j   Bekker, Linda Gail ^c   Freedberg, Kenneth A ^a,b,j,k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e TUFTS MEDICAL CENTER   (United States)

^f TUFTS UNIVERSITY   (United States)

^g YALE UNIVERSITY   (United States)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FEMALE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LABORATORY DIAGNOSIS; LIFE EXPECTANCY; MALE; MOBILE HIV SCREENING; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SURVIVAL RATE; ACQUIRED IMMUNODEFICIENCY SYNDROME; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HIV INFECTIONS; MASS SCREENING; OUTCOME ASSESSMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL; YOUNG ADULT;

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MOBILE HEALTH UNITS; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; SOUTH AFRICA; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84899887387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085197     Document Type: Article

References (59)

1. UNAIDS HIV and AIDS Estimates (2009). Available: http://www.unaids.org/ en/regionscountries/countries/southafrica/. Accessed 23 July 2013.
2. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, et al. (2003) Medium-term survival, morbidity and immunovirological evolution in HIVinfected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 8: 385-393. (Pubitemid 37351556)
3. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, et al. (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24: 123-137.
4. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224. (Pubitemid 40962502)
5. Venkatesh KK, Lurie MN, Mayer KH (2012) How HIV treatment could result in effective prevention. Future Virol 5: 405-415.
6. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
7. Dieffenbach CW, Fauci AS (2009) Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 301: 2380-2382.
8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
9. Matsoso MP (2012) Letter Re: Accelerating Access to ART Services and Uptake Pretoria: South Africa Department of Health. Available: http://www.tbonline.info/media/uploads/documents/changes-to-art-guidelines.pdf. Accessed 23 July 2013.
10. South Africa National Department of Health Strategic Plan 2010/11-2012/13. Pretoria. Available: http://www.mm3admin.co.za/documents/ docmanager/2D5ED792-878C-4371-9575-8281A96BBB26/00023294.pdf. Accessed 23 July 2013.
11. SANAC National Strategic Plan on HIV, STIs and TB 2012-2016. Available: http://www.info.gov.za/view/DownloadFileAction?id = 155622. Accessed 23 July 2013.
12. Republic of South Africa Global Response Progress Report (2012). Available: http://www.unaids.org/en/dataanalysis/knowyourresponse/ countryprogressreports/2012countries/ce-ZA-Narrative-Report.pdf.Accessed 23 July 2013.
13. Ahmed S, Delaney K, Villalba-Diebold P, Aliyu G, Constantine N, et al. (2013) HIV counseling and testing and access-to-care needs of populations most-at-risk for HIV in Nigeria. AIDS Care 25: 85-94.
14. Maheswaran H, Thulare H, Stanistreet D, Tanser F, Newell ML (2012) Starting a home and mobile HIV testing service in a rural area of South Africa. J Acquir Immune Defic Syndr 59: e43-46.
15. Morin SF, Khumalo-Sakutukwa G, Charlebois ED, Routh J, Fritz K, et al. (2006) Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. J Acquir Immune Defic Syndr 41: 218-224.
16. Ostermann J, Reddy EA, Shorter MM, Muiruri C, Mtalo A, et al. (2011) Who tests, who doesn't, and why? Uptake of mobile HIV counseling and testing in the Kilimanjaro Region of Tanzania. PLoS One 6: e16488.
17. Sweat M, Morin S, Celentano D, Mulawa M, Singh B, et al. (2011) Communitybased intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis 11: 525-532.
18. van Schaik N, Kranzer K, Wood R, Bekker LG (2010) Earlier HIV diagnosis- are mobile services the answer? S Afr Med J 100: 671-674.
19. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, et al. (2011) Firstline antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25: 479-492.
20. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Côte d'Ivoire. N Engl J Med 355: 1141-1153. (Pubitemid 44394920)
21. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157-166.
22. Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, et al. (2011) The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 56: 26-35.
23. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, et al. (2008) Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 197: 1324-1332. (Pubitemid 351632764)
24. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21: S117-128. (Pubitemid 47051757)
25. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, et al. (2005) Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 19: 1299-1308. (Pubitemid 41224899)
26. Govindasamy D, Kranzer K, van Schaik N, Noubary F, Wood R, et al. (2013) Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS One 8: e80017.
27. Gold M, JE. S, Russell L, Weinstein MC, editors(1996) Cost Effectiveness in Health and Medicine. New York: Oxford University Press.
28. WHO (2012) CHOosing Interventions that are Cost Effective (WHOCHOICE): Cost-effectiveness thresholds. Geneva: World Health Organization. Available: http://www.who.int/choice/costs/CER-thresholds/en/index.html. Accessed 23 July 2013.
29. IMF (2012) International Monetary Fund World Economic Outlook Database, April 2012. Available: http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/ weorept.aspx?sy=2005&ey=2015&scsm=1&ssd=1&sort=country&ds=. &br=1&pr1.x=50&pr1.y=8&c=199&s=NGDPDPC&grp=0&a=. Accessed 23 July 2013.
30. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831. (Pubitemid 32222162)
31. Paltiel AD, Walensky RP, Schackman BR, Seage GR, 3rd, Mercincavage LM, et al. (2006) Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 145: 797-806. (Pubitemid 351650333)
32. SANAC (2010) South Africa National Department of Health Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents. Available: http://www.who.int/hiv/pub/guidelines/south-africa-art.pdf. Accessed 23 July 2013.
33. The Clinton Foundation HIV/AIDS Initiative. Antiretroviral price list (2012). Available: http://d2pd3b5abq75bb.cloudfront.net/2012/07/12/15/03/07/163/ CHAI-ARV-Ceiling-Price-List-May-2012.pdf. Accessed 23 July 2013.
34. Cleary S, Boulle A, McIntyre D, Coetzee D (2004) Cost-Effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Médecins Sans Frontières and the Health Systems Trust. Available: http://www.healthlink.org.za/publications/579. Accessed 23 July 2013.
35. Cleary S, Okorafor O, Chitha W, Boulle A, Jikwana S (2005) South African Health Review: Chapter 5 - Financing Antiretroviral Treatment and Primary Health Care Services. Durban: Health Systems Trust. Available: http://www.healthlink. org.za/uploads/files/sahr05-chapter5.pdf. Accessed 23 July 2013.
36. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260. (Pubitemid 43113030)
37. Hammond R, Harry TC (2008) Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures - a meta-analysis. Int J STD AIDS 19: 291-296. (Pubitemid 351748268)
38. Holmes CB, Wood R, Badri M, Zilber S, Wang B, et al. (2006) CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 42: 464-469. (Pubitemid 44050895)
39. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, et al. (2005) Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19: 685-694. (Pubitemid 40593073)
40. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954. (Pubitemid 27255797)
41. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52-59. (Pubitemid 46684443)
42. Govindasamy D, van Schaik N, Kranzer K, Wood R, Mathews C, et al. (2011) Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defic Syndr 58: 344-352.
43. Larson BA, Brennan A, McNamara L, Long L, Rosen S, et al. (2010) Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ 88: 675-680.
44. SANAC (2010) The South African Antiretroviral Treatment Guidelines. South Africa Department of Health. Available: http://www.uj.ac.za/EN/ CorporateServices/ioha/Documentation/Documents/ART%20Guideline.pdf. Accessed 23 July 2013.
45. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, et al. (2007) Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr 46: 181-186. (Pubitemid 47482613)
46. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, et al. (2007) Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 10: 336-347. (Pubitemid 47481105)
47. Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions - standardizing data on outcomes. N Eng J Med 339: 380-386. (Pubitemid 28363802)
48. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, et al. (2004) Screening for type 2 diabetes mellitus: a cost-effectivness analysis. Ann Intern Med 140: 689-699.
49. Shisana O, Rehle T, Simbayi L, Parker W, Jooste S, et al. (2009) South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008. Cape Town: HSRC Press.
50. Statistics South Africa: Mid-year population estimates 2011. P0302 ed. Pretoria: Statistics South Africa.
51. Medecins Sans Frontieres: Khayelitsha Annual Activity Report (2004-2009). Available: http://www.msf.or.jp/info/pressreport/pdf/2009-hiv01.pdf. Accessed 23 July 2013.
52. van Rooyen H, McGrath N, Chirowodza A, Joseph P, Fiamma A, et al. (2012) Mobile VCT: reaching men and young people in urban and rural South African pilot studies (NIMH Project Accept, HPTN 043). AIDS Behav 11.
53. Babigumira JB, Sethi AK, Smyth KA, Singer ME (2009) Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 27: 963-973.
54. Western Cape Budget Overview (2012). Available: http://www.westerncape. gov.za/Text/2012/3/2012-wc-overview-of-pre-%2824-feb-2012%29-f.pdf. Accessed 23 July 2013.
55. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD (2008) HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav 12: 363-373.
56. National Treasury of the Republic of South Africa Budget Review (2012). Available: http://www.treasury.gov.za/documents/national%20budget/2012/review/ Prelims%202012.pdf. Accessed 23 July 2013.
57. Lyamuya EF, Aboud S, Urassa WK, Sufi J, Mbwana J, et al. (2009) Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 9: 19.
58. Fox MP, Rosen S (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 1: 1-15.
59. Brinkhof MW, Pujades-Rodriguez M, Egger M (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 4: e5790.